Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson’s: a systematic review

Xin, Yiqiao; McIntosh, Emma

doi:10.1007/s11136-016-1428-x

Cited by 22 publications

(15 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EQ‐5D‐5L had increased sensitivity, higher precision, lower bias, and decreased ceiling effect in measuring health status compared to the EQ‐5D‐3L (Janssen et al., 2018 ; Thompson & Turner, 2020 ). In addition, EQ‐5D‐5L was proved to have good evidence of discriminant validity, while EQ‐5D‐3L was less sensitive in patients with PD (Xin & McIntosh, 2017 ). A few studies have focused on the HRQoL of MSA by using the EQ‐5D‐3L (Du et al., 2018 ; Higginson et al., 2012 ; Schrag et al., 2006 ; Winter et al., 2011 ).…”

Section: Introductionmentioning

confidence: 99%

Health‐related quality of life in patients with multiple system atrophy using the EQ‐5D‐5L

et al. 2022

View full text Add to dashboard Cite

Background Multiple system atrophy (MSA) is an incurable neurodegenerative disease. We aimed to investigate the health‐related quality of life (HRQoL) and the determinants of HRQoL in patients with MSA. Methods The five‐level EuroQol five‐dimensional questionnaire (EQ‐5D‐5L) was used to evaluate patients’ HRQoL. The results of HRQoL were indicated by the EQ‐5D‐5L index values and visual analog scale (EQ VAS) scores. Specific scales were used to measure disease severity, cognition, frontal lobe function, anxiety, depression, fatigue, and sleep disorders. The beta mixture model and the linear regression model were used to explore the determinants of HRQoL in patients with MSA. Results A total of 205 patients with cerebellar variants (MSA‐C; 53.9%) and 175 patients with parkinsonian variants (MSA‐P; 46.1%) were included in this cross‐sectional study. The mean values of the EQ‐5D‐5L index values and EQ VAS scores were .558 and 59.5, respectively. Problem with mobility was the problem reported by the highest proportion of patients (92.1%), followed by problems with usual activities (88.7%), self‐care (81.3%), anxiety/depression (72.1%), and pain/discomfort (53.9%). The determinants of the lower EQ‐5D‐5L index values in patients with MSA were greater disease severity, fatigue, Parkinson's disease‐related sleep problems (PD‐SP), depressive mood, and anxious mood. Greater disease severity, fatigue, and depressive mood were associated with lower EQ VAS scores. Conclusion The problem reported most frequently by Chinese individuals with MSA was mobility. In addition to the greater disease severity of MSA, fatigue, PD‐SP, depression, and anxiety were determinants of poor HRQoL.

show abstract

Section: Introductionmentioning

confidence: 99%

Health‐related quality of life in patients with multiple system atrophy using the EQ‐5D‐5L

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Various pain scales have been utilized in PD studies, but many of these tools are not suitable for use in routine clinical care due to their time requirements [15]. Thus, an efficient pain screening strategy might encompass profiling pain using generic health-related quality of life (HRQoL) tools that have shown construct validity in PWP [16]. One such generic tool is the EuroQol 5 dimensions with five response levels (EQ-5D-5L), which measures mobility, self-care, daily activities, anxiety and depression, and pain and discomfort [17].…”

Section: Introductionmentioning

confidence: 99%

Heterogeneous pain trajectories in persons with Parkinson's disease

Gunzler

Briggs

2022

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

“…Joo et al studied the morphology, adhesion, and proliferation of cells on PVC pipes with different coatings. For the coating of cell adhesion, it is mainly determined by the uniformity of the coating rather than the coating material [ 4 ]. Leiter et al used a photochemical fixation method to covalently bond dipyridamole to the polyurethane surface.…”

Section: Introductionmentioning

confidence: 99%

Role of Folic Acid Drugs in the Treatment with Antithrombotic and Anticoagulant Drugs for Patients with Cardiovascular Diseases Based on the Analysis of Virtual Reality Medical Data

Zhang

Wang

Qiang

2021

Journal of Healthcare Engineering

View full text Add to dashboard Cite

In recent years, with the continuous progress and development of science and technology and the increasing maturity of medical technology, the incidence of cardiovascular diseases has gradually increased with the age of the population. In the case of cardiovascular disease, proper anticoagulant therapy can effectively prevent bleeding in the occurrence of events, so a more effective treatment of cardiovascular disease is considered a difficult problem to overcome. Therefore, this article proposes the role of folic acid drugs based on virtual reality medical data analysis in the treatment of cardiovascular disease patients with antithrombotic and anticoagulant drugs, in order to improve providing help for cardiovascular disease. This study selected patients with cardiovascular disease who were admitted to the hospital and extracted 100 patients with complete data and a one-year follow-up period, covering the overall status of the patients’ cardiovascular risk factors, cardiovascular disease degree, and the occurrence of major cardiovascular adverse events. During the follow-up period, we analyzed the specific status of major cardiovascular adverse events and the occurrence of bleeding events and compared and analyzed the effects of folic acid drugs on the treatment with antithrombotic and anticoagulant drugs in patients with cardiovascular disease. Experiments have proved that the differences in the degree of cardiovascular stenosis and the number of cardiovascular disease vessels in the four groups are statistically significant ( P < 0.01 ). The degree of cardiovascular stenosis in group D was lighter than that in groups A, B, and C, and the number of cardiovascular lesions was also less than that in groups A, B, and C. The differences were statistically significant ( P < 0.05 ). This indicates that folic acid can effectively treat cardiovascular stenosis, prevent cardiovascular disease, and then treat patients with cardiovascular disease with antithrombotic and anticoagulant drugs. It provides an important basis for accurate clinical diagnosis and treatment.

show abstract

Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson’s: a systematic review

Cited by 22 publications

References 84 publications

Health‐related quality of life in patients with multiple system atrophy using the EQ‐5D‐5L

Health‐related quality of life in patients with multiple system atrophy using the EQ‐5D‐5L

Heterogeneous pain trajectories in persons with Parkinson's disease

Role of Folic Acid Drugs in the Treatment with Antithrombotic and Anticoagulant Drugs for Patients with Cardiovascular Diseases Based on the Analysis of Virtual Reality Medical Data

Contact Info

Product

Resources

About